| Fazio, Nicola |
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) | ITM Solucin GmbH | Neuroendocrine Tumors | 06/27 | 09/27 | | |
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma |
|
|
| Recruiting | 3 | 200 | Europe, US, RoW | Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma | 05/26 | 08/26 | | |
MeTe, NCT05554003: Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): Study |
|
|
| Recruiting | 2 | 46 | Europe | Temozolomide capsule | European Institute of Oncology | Neuroendocrine Tumors, Frailty, Chemotherapy Effect | 12/24 | 12/24 | | |
| Recruiting | N/A | 50 | Europe | | European Institute of Oncology | Neuroendocrine Tumors, COVID-19 | 12/23 | 12/23 | | |
NCT06790251: Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database) |
|
|
| Not yet recruiting | N/A | 600 | Europe | | F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore | Multiple Endocrine Neoplasia Type 1 | 05/35 | 05/35 | | |
MONET, NCT04720391: Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach |
|
|
| Recruiting | N/A | 500 | Europe | | European Institute of Oncology | Bone Metastases, Neuroendocrine Neoplasm | 12/21 | 12/21 | | |
